Equity

6 Months Ended

Jun. 30, 2012

Equity [Abstract]

Equity

7. Equity

 Warrants

BioTime has issued warrants to purchase its common shares as payments for services and in connection to certain business acquisitions.  At June 30, 2012, 636,613 warrants to purchase common shares with a weighted average exercise price of $9.12 and a weighted average remaining contractual life of 1.19 years were outstanding.

Preferred Shares

BioTime is authorized to issue 1,000,000 shares of preferred stock.  The preferred shares may be issued in one or more series as the board of directors may by resolution determine.  The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.  The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.

As of June 30, 2012 BioTime has no issued and outstanding preferred shares.

Common Shares

BioTime is authorized to issue 75,000,000 common shares with no par value.  As of June 30, 2012, BioTime had issued and outstanding 50,790,391 common shares.

During the three and six months ended June 30, 2012, no options or warrants were exercised.

During the six months ended June 30, 2012 and 2011, BioTime recognized stock-based compensation expenses of $929,257 and $846,273, respectively, due to stock options granted to employees and directors.  During the six months ended June 30, 2012 and 2011, BioTime granted 130,000 and 96,593 options, respectively, under its 2002 Stock Option Plan.